Skip to main content

Table 2 The difference of tumor response between two groups, n (%)

From: The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study

Tumor response

AG (n = 24)

FFX (n = 20)

P value

Objective response rate(%)

16.7%

20.0%

0.775

Complete response (CR)

0 (0.0)

0 (0.0)

Partial response (PR)

4 (16.7)

4 (20.0)

Stable disease (SD)

13 (54.2)

8 (40.0)

Progressive disease (PD)

7 (29.2)

8 (40.0)

Disease control rate (PR + SD)

17 (70.8)

11 (60.0)